Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BGC-0228 by BrightGene Bio-Medical Technology for Gastric Cancer: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Gastric Cancer. According to GlobalData,...
BGC-0228 by BrightGene Bio-Medical Technology for Solid Tumor: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Solid Tumor. According to GlobalData,...
BGC-0228 by BrightGene Bio-Medical Technology for Metastatic Pancreatic Cancer: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Metastatic Pancreatic Cancer. According to...
BGC-0228 by BrightGene Bio-Medical Technology for Small-Cell Lung Cancer: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Small-Cell Lung Cancer. According to...
BGC-0228 by BrightGene Bio-Medical Technology for Colorectal Cancer: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Colorectal Cancer. According to GlobalData,...
BGC-0228 by BrightGene Bio-Medical Technology for Esophageal Cancer: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Esophageal Cancer. According to GlobalData,...
BGC-0228 by BrightGene Bio-Medical Technology for Esophageal Cancer: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Esophageal Cancer. According to GlobalData,...
BGC-0228 by BrightGene Bio-Medical Technology for Colorectal Cancer: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Colorectal Cancer. According to GlobalData,...
BGC-0228 by BrightGene Bio-Medical Technology for Small-Cell Lung Cancer: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Small-Cell Lung Cancer. According to...
BGC-0228 by BrightGene Bio-Medical Technology for Metastatic Pancreatic Cancer: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Metastatic Pancreatic Cancer. According to...
BGC-0228 by BrightGene Bio-Medical Technology for Solid Tumor: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Solid Tumor. According to GlobalData,...
BGC-0228 by BrightGene Bio-Medical Technology for Gastric Cancer: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Gastric Cancer. According to GlobalData,...
BGC-0228 by BrightGene Bio-Medical Technology for Breast Cancer: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Breast Cancer. According to GlobalData,...
BGC-0228 by BrightGene Bio-Medical Technology for Epithelial Ovarian Cancer: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Epithelial Ovarian Cancer. According to...
BGC-0228 by BrightGene Bio-Medical Technology for Non-Small Cell Lung Cancer: Likelihood of Approval
BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Non-Small Cell Lung Cancer. According...